Schedule 13D ownership disclosure

TEMPEST THERAPEUTICS INC

Common Stock, par value $0.001 per share · CUSIP: 87978U108

Event date: 2024-11-12

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Versant Venture Capital VI, L.P.Reported CIK 0001687880

    Shares: 209,914 · Class: 0.5%

  • Versant Ventures VI GP, L.P.Reported CIK 0001777654

    Shares: 209,914 · Class: 0.5%

  • Versant Ventures VI GP-GP, LLCReported CIK 0001777652

    Shares: 209,914 · Class: 0.5%

  • Versant Vantage II, L.P.Reported CIK 0001832235

    Shares: 2,118,644 · Class: 4.8%

  • Versant Vantage II GP, L.P.Reported CIK 0001839790

    Shares: 2,118,644 · Class: 4.8%

  • Versant Vantage II GP-GP, LLCReported CIK 0001839789

    Shares: 2,118,644 · Class: 4.8%

  • Versant Venture Capital IV, L.P.Reported CIK 0001456590

    Shares: 1,171,094 · Class: 2.7%

  • Versant Side Fund IV, L.P.Reported CIK 0001456591

    Shares: 7,377 · Class: 0.0%

  • Versant Ventures IV, LLC

    Shares: 1,178,471 · Class: 2.7%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000950170-25-018140
Form type
SCHEDULE 13D/A
Filer
Tempest Therapeutics, Inc.
CIK
CIK 1544227
Filed
Feb 11, 2025
Reporting period
Nov 12, 2024
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub